Subsequent Event |
3 Months Ended |
---|---|
Mar. 31, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Event |
10. Subsequent Event
On April 7, 2020, the Company committed to an operational plan to reduce overall operating expenses, including a workforce reduction of approximately 53 percent. The workforce reduction will primarily affect the ZULRESSO™ (brexanolone) CIV injection commercial operation and related Selling, General and Administrative (“SG&A”) support functions. The Company remains committed to working with healthcare providers and patients seeking access to ZULRESSO, but commercial efforts will be primarily focused on geographies that have existing, active ZULRESSO treating sites. The Company expects to record a charge of approximately $31 million in the second quarter of 2020 as a result of the workforce reduction, consisting of one-time termination benefits for employee severance, benefits, and related costs, substantially all of which will be paid out over the next nine months. |